Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds

Health and Quality of Life Outcomes

Volumn 12, Issue 1, 2014, Pages

  Strand, Vibeke ^a   Kosinski, Mark ^b   Gnanasakthy, Ari ^c   Mallya, Usha ^c   Mpofu, Shephard ^c  

^a STANFORD UNIVERSITY   (United States)

^b QualityMetric Incorporated   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; PLACEBO; SECUKINUMAB;

ADULT; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DRUG EFFICACY; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE; HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SHORT FORM 36; SIMPLIFIED DISEASE ACTIVITY INDEX; TREATMENT DURATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISABILITY EVALUATION; DRUG THERAPY, COMBINATION; FEMALE; HEALTH STATUS; HEALTH SURVEYS; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PLACEBOS; QUALITY OF LIFE; QUESTIONNAIRES; RECOVERY OF FUNCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84897954122     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-12-31     Document Type: Article

References (39)

1. Symmons D, Turner G, Webb R, Asten P, Barrett E, Lunt M, Scott D, Silman A. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology 2002, 41:793-800. 10.1093/rheumatology/41.7.793, 12096230.
2. Jordan K, Clarke AM, Symmons DP, Fleming D, Porcheret M, Kadam UT, Croft P. Measuring disease prevalence: a comparison of musculoskeletal disease using four general practice consultation databases. Br J Gen Pract 2007, 57:7-14. 2032694, 17244418.
3. Rodriguez LA, Tolosa LB, Ruigomez A, Johansson S. Rheumatoid arthritis in UK primary care: incidence and prior morbidity. Scand J Rheumatol 2009, 38:173-177. 10.1080/03009740802448825, 19117247.
4. Ward MM, Javitz HS, Yelin EH. The direct costs of rheumatoid arthritis. Value Health 2000, 3:243-252. 10.1046/j.1524-4733.2000.34001.x, 16464188.
5. Wolfe F, Michaud K, Choi HK, Williams R. Household income and earnings losses among 6,396 persons with rheumatoid arthritis. J Rheumatol 2005, 32(10):1875-1883.
6. Kessler RC, Maclean JR, Petukhova M, Sarawate CA, Short L, Li TT, Stang PE. The effects of rheumatoid arthritis on labor force participation, work performance, and healthcare costs in two workplace samples. Occup Environ Med 2008, 50:88-98.
7. Ozminkowski R, Burton WN, Goetzel RZ, MacLean R, Wang S. The impact of rheumatoid arthritis arthritis on medical expenditures, absenteeism, and short-term disability benefits. J Occup Environ Med 2006, 48:135-148. 10.1097/01.jom.0000194161.12923.52, 16474262.
8. van Jaarsveld CH, Jacobs JW, Schrijvers AJ, Albada-Kuipers GA, Hofman DM, Bijlsma JW. Effects of rheumatoid arthritis on employment and social participation during the first years of disease in The Netherlands. Br J Rheumatol 1998, 37(8):848-853. 10.1093/rheumatology/37.8.848, 9734675.
9. Sokka T, Abelson B, Pincus T. Mortality in rheumatoid arthritis" 2008 update. Clin Exp Rheumatol 2008, 26:S35-S61.
10. Wasserman AM. Diagnosis and treatment of rheumatoid arthritis. Am Fam Physician 2011, 84(11):1245-1252.
11. Kosinski M, Kujawski SC, Martin R, Wanke LA, Buatti MC, Ware JE, Perfetto EM. Health-Related Quality of Life in Early Rheumatoid Arthritis: impact of disease and treatment response. Am J Manage Care 2002, 8(3):231-240.
12. Talamo J, Frater A, Gallivan S, Young A. Use of the Short Form 36 (SF36) for health status measurement in rheumatoid arthritis. Br J Rheumatol 1997, 36(4):463-469. 10.1093/rheumatology/36.4.463, 9159541.
13. Suurmeijer TPBM, Waltz M, Moum T, Guillemin F, van Sonderen FLP, Briancon S. Quality of life profiles in the first years of rheumatoid arthritis: results from the EURIDISS longitudinal study. Arthritis Rheum 2001, 45:111-121. 10.1002/1529-0131(200104)45:2<111::AID-ANR162>3.0.CO;2-E, 11324773.
14. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Suarez Almazor M, Bridges SL, Chatham WW, Hochberg M, MacLean C, Mikuls T, Moreland LW, ODell J, Turkiewicz AM, Furst DE, . American College of Rheumatology American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008, 59(6):762-784. 10.1002/art.23721, 18512708, American College of Rheumatology.
15. Pincus T, Brooks RH, Callahan LF. Prediction of long term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Ann Intern Med 1994, 120:26-34. 10.7326/0003-4819-120-1-199401010-00005, 8250453.
16. Terry RB, Singh G. Quality of life measures in the treatment of arthritis in clinical practice. New Standards Arthritis Care 1996, 5(3):2-6.
17. Schiff M, Weaver A, Keystone E, Moreland L, Spencer-Green G. Comparison of ACR response, numeric ACR, and ACR AUC as measures of clinical improvement in clinical trials. Arthritis Rheum 1999, 42(Suppl 9):S81.
18. Siegel JN, Zhen B. Use of the American College of Rheumatology N (ACR-N) Index of Improvement in Rheumatoid Arthritis: Argument in Favor. Arthritis Rheum 2005, 52(6):1637-1641. 10.1002/art.21243, 15934067.
19. Boers M. Use of the American College of Rheumatology N (ACR-N) Index of Improvement in Rheumatoid Arthritis: Argument in Opposition. Arthritis Rheum 2005, 52(6):1642. customerservice@eastonsports.com1645customerservice@eastonsports.comcustomerservice@eastonsports.com, 10.1002/art.21106, 15934132.
20. Aletaha D, Ward MM, Machold KP, Nell VPK, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis. Arthritis Rheum 2005, 52(9):2625-2636. 10.1002/art.21235, 16142705.
21. Fries J, Spitz P, Young D. The dimensions of health outcomes: the Health Assessment Questionnaire. J Rheumatol 1982, 9:789-793.
22. Ware JEJ, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30(6):473-483. 10.1097/00005650-199206000-00002, 1593914.
23. Ware JEJ, Kosinski M, Dewey JE. How to Score Version 2 of the SF-36 Health Survey (Standard & Acute Forms) 2000, QualityMetric Incorporated: Lincoln, RI, 2.
24. Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes 2003, 1:79. 10.1186/1477-7525-1-79, 317391, 14678568.
25. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993, 11(3):570-579.
26. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997, 34(3 Suppl 2):13-19.
27. Kerlinger FN. Foundations of behavioral research 1973, New York: Holt, Rinehart and Winston.
28. Zatarain E, Strand V. Monitoring disease activity of rheumatoid arthritis in clinical practice: contributions from clinical trials. Rheumatol 2006, 2(11):611-618.
29. Aletaha D, Smolen J. The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005, 23(Suppl. 39):S100-S108. customerservice@eastonsports.com.
30. Strand V, Mease P, Burmester GR, Nikai E, Coteur G, van Vollenhoven R, Combe B, Keystone EC, Kavanaugh A. Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial. Arthritis Res Ther 2009, 11(6):R170. 10.1186/ar2859, 3003523, 19909548.
31. Strand V, Boers M, Idzerda L, Kirwan JR, Kvien TK, Tugwell PS, Dougados M. It's good to feel better but it's better to feel good and even better to feel good as soon as possible for as long as possible. Response criteria and the importance of change at OMERACT 10. J Rheumatol 2011, 38(8):1720-1727. 10.3899/jrheum.110392, 21807792.
32. Farrar JT, Portenoy RK, Berlin JA, Kinman J, Strom BL. Defining the clinically important difference in pain outcome measures. Pain 2000, 88:287-294. 10.1016/S0304-3959(00)00339-0, 11068116.
33. Ware JE, Kosinski M, Bjorner JB, Turner-Bowker DM, Gandek B, Maruish M. Users manual for the SF-36v2 Health Survey 2007, QualityMetric: Lincoln, RI, 2.
34. Strand V, Smolen JS, van Vollenhoven RF, Mease P, Burmester G, Hiepe F, Khanna D, Nikaï E, Coteur G, Schiff M. Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient reported outcomes from the RAPID 2 trial. Ann Rheum Disord 2011, 70:996-1002.
35. Strand V, Burmester G, Ogale S, Devenport J, John A, Emery P. Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumor necrosis factor inhibitors: results from a 24-week randomized controlled RADIATE study. Rheumatol 2012, doi:10.1093/rheumatology/kes131.
36. Ware JE, Kosinski M, Bjorner JB, Turner-Bowker DM, Gandek B, Maruish ME. Users Manual for the SF-36v2 Health Survey. 2nd Edition ed 2007, QualityMetric Incorporated: Lincoln, RI.
37. Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol 2005, 32(5):811-819.
38. Cohen J. Statistical power for the behavioral sciences 1988,
39. Wolfe F, Michaud K, Strand V. Expanding the definition of clinical differences: From minimally clinically important differences to really important differences. Analyses in 8931 patients with rheumatoid arthritis. J Rheumatol 2005, 23:583-589.